InnoCare Pharma Ltd.SSE: 688428

Announcement on Shareholding Reduction Plan for Directors and Senior Management Members

Jun 25, 2026 · Issued by InnoCare Pharma Ltd. via Shanghai Stock Exchange

Filed with SSE · Jun 25, 2026

On 6ix: 6ix.com/news/announcement-on-shareholding-reduction-plan-for-directors-and-senior-management-members-22

Announcement on Shareholding Reduction Plan for Directors and Senior Management Members

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

InnoCare Pharma Ltd. on 6ix

Earlier from InnoCare Pharma

Announcement on Vesting Results of the 1st Vesting Period of Those Initially Granted in 2024 STAR Market Restricted Stock Incentive Plan and Listing of SharesJun 24
Self-Inspection Report on the Trading of Company's Stock by Information Insiders in 2026 STAR Market Restricted Stock Incentive PlanJun 17
2026 EHA | Over 40 Orelabrutinib Studies Presented, Including First Clinical Data from Europe and US TN CLL/SLL PatientsJun 15
Publicity Explanation and Verification Opinions of the Remuneration Committee of the Board of Directors on List of Initially Granted Incentive Objects in the 2026 STAR Market Restricted Stock Incentive PlanJun 10
Phase IIb Study Results of InnoCare’s Orelabrutinib in Patients with SLE Presented at 2026 EULARJun 5

Later from InnoCare Pharma

InnoCare Announces First Patient Dosed in Clinical Trial of Novel CDH17 targeted ADC ICP-B208 in ChinaJul 5
Study Results of Orelabrutinib in Patients with SLE Published in the Journal of AutoimmunityJul 10
InnoCare Announces Publication in STTT (IF=81.2) of Phase 3 Results Showing Orelabrutinib Significantly Prolonged Progression-Free Survival in Treatment-Naïve CLL/SLLJul 14
InnoCare Announces Phase III Study Results of TYK2 Inhibitor Soficitinib Meet Primary Endpoint in Patients with Atomic DermatitisJul 15
Announcement on Voluntary Disclosure of Soficitinib (ICP-332) Achieving the Primary Endpoint in a Phase II Study for the Treatment of Non-segmental VitiligoJul 17

All InnoCare Pharma news releases

Follow InnoCare Pharma into a list and get an email when it puts out news.

Follow InnoCare Pharma